title: Intravitreal administration of bevacizumab in the treatment of choroidal metastasis in a patient with erlotinib-failed pulmonary adenocarcinoma.
abstract: Choroidal metastasis is uncommon and usually identified in a relatively advanced cancer status. The median survival after diagnosing choroid metastasis in lung cancer patients was only 1.9 months. Once failed to systemic treatment, there was no effective local treatment for saving visual acuity. The off-label use of intravitreal bevacizumab was popular in treating VEGF-mediated chorioretinal diseases worldwide. We here demonstrate a dramatic and durable response to intravitreal bevacizumab. Unlike the previous similar reports, our patient had failed both first- and second-line therapies.
authors.affiliation: Division of Pulmonology and Critical Care, Department of Internal Medicine, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan.
authors.forename: Chun-Liang
authors.initials: CL
authors.lastname: Lai
authors.forename: Kuo-Sheng
authors.initials: KS
authors.lastname: Fan
authors.forename: Yen-Hsien
authors.initials: YH
authors.lastname: Lee
authors.forename: Hsing-Chun
authors.initials: HC
authors.lastname: Chen
authors.forename: Wen-Hsiung
authors.initials: WH
authors.lastname: Fan
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D002830:Choroid Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D006801:Humans; D058449:Intravitreal Injections; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D009367:Neoplasm Staging; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab